Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mirvetuximab Soravtansine→

Mirvetuximab Soravtansine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1453084-37-1
Molecular formula
Not available
Molecular weight
Not available
Drug class
Folate receptor alpha (FRα)-directed antibody–drug conjugatemicrotubule inhibitor payload
Mechanism of action
The antibody binds FRα on tumour cells and is internalised. Intracellular cleavage releases DM4, a maytansinoid microtubule inhibitor that disrupts the microtubule network, causing cell-cycle arrest and apoptotic cell death.
Indications / reported uses
  • Treatment of adults with FRα-positive, platinum-resistant epithelial ovarian, fallopian-tube or primary peritoneal cancer after one to three prior systemic treatment regimens, using an FDA-authorised FRα test; see current label for eligibility and ocular monitoring

Sources: US DailyMed — ELAHERE (mirvetuximab soravtansine-gynx) · NICE — Mirvetuximab soravtansine guidance, 24 June 2026 · Health Canada — ELAHERE product status · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Folate receptor alpha (FRα)-directed antibody–drug conjugate; microtubule inhibitor payload

Mechanism of action

The antibody binds FRα on tumour cells and is internalised. Intracellular cleavage releases DM4, a maytansinoid microtubule inhibitor that disrupts the microtubule network, causing cell-cycle arrest and apoptotic cell death.

General use cases

  • Treatment of adults with FRα-positive, platinum-resistant epithelial ovarian, fallopian-tube or primary peritoneal cancer after one to three prior systemic treatment regimens, using an FDA-authorised FRα test; see current label for eligibility and ocular monitoring

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Mirvetuximab Soravtansine Environmental Risk Assessment (ERA) (the Mirvetuximab Soravtansine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.